Andrew Ambrosy to Benzazepines
This is a "connection" page, showing publications Andrew Ambrosy has written about Benzazepines.
Connection Strength
2.222
-
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
Score: 0.540
-
Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb; 165(2):216-25.
Score: 0.429
-
Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother. 2011 Apr; 12(6):961-76.
Score: 0.379
-
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
Score: 0.134
-
Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
Score: 0.132
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
Score: 0.111
-
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013 Jan; 6(1):47-52.
Score: 0.107
-
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
Score: 0.107
-
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012 May; 17(3):485-509.
Score: 0.102
-
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72.
Score: 0.097
-
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
Score: 0.030
-
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
Score: 0.027
-
Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2012 Nov; 5(6):750-8.
Score: 0.026